Brokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $8.00

Aquestive Therapeutics, Inc. (NASDAQ:AQSTGet Free Report) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $8.00.

AQST has been the topic of a number of recent research reports. Raymond James assumed coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $7.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday. Piper Sandler started coverage on Aquestive Therapeutics in a research report on Thursday, April 11th. They set an “overweight” rating and a $10.00 price objective for the company. Leerink Partnrs raised shares of Aquestive Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. Finally, JMP Securities increased their price target on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th.

Check Out Our Latest Stock Analysis on AQST

Insider Activity

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider now owns 984,476 shares of the company’s stock, valued at $5,906,856. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 7.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in Aquestive Therapeutics during the 1st quarter worth $54,000. Lazard Asset Management LLC grew its stake in shares of Aquestive Therapeutics by 115.5% in the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after buying an additional 15,601 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at about $60,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after acquiring an additional 30,898 shares in the last quarter. Finally, PFG Investments LLC purchased a new position in Aquestive Therapeutics in the 1st quarter worth approximately $204,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $2.81 on Tuesday. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The stock’s fifty day moving average is $3.57 and its two-hundred day moving average is $3.13. The firm has a market capitalization of $255.82 million, a price-to-earnings ratio of -6.69 and a beta of 2.81.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last announced its earnings results on Monday, May 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The business had revenue of $12.05 million for the quarter, compared to the consensus estimate of $12.22 million. During the same period in the prior year, the firm posted $0.11 EPS. As a group, sell-side analysts forecast that Aquestive Therapeutics will post -0.42 EPS for the current fiscal year.

About Aquestive Therapeutics

(Get Free Report

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Featured Articles

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with's FREE daily email newsletter.